Teva names Eric Hughes as R&D head and CMO

Israeli generics giant Teva Pharmaceutical Industries announced today the appointment of Eric Hughes as executive vice president, global R&D and chief medical officer. Dr Hughes will begin his employment on August 1, 2022, and will be based out of Teva’s US headquarters in Parsippany, New Jersey.

Dr Hughes joins Teva with nearly 20 years of experience in all phases of drug development in leading global pharmaceutical companies, most…

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. The Pharma Letter